Filtered By:
Vaccination: Malaria Vaccine

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 69 results found since Jan 2013.

Evaluation of the adjuvant activity of propranolol, a Beta-adrenergic receptor antagonist, on efficacy of a malaria vaccine model in BALB/c mice.
In this study PRP was used as an adjuvant in combination with Plasmodium berghei (P. berghei) whole blood stage (PWBS) antigens. BALB/c mice were immunized three times with a 2-week interval, either PWBS vaccine alone or in combination with the adjuvant alum or propranolol. The control group received phosphate buffered saline. Evaluation of the cellular and humoral immunity was performed by measurement of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, lymphocyte proliferation, total IgG and IgG2a in the control and immunized groups. Furthermore, Clinical evaluations were carried out by analyze survival rate and paras...
Source: Iranian Journal of Allergy, Asthma and Immunology - August 31, 2014 Category: Allergy & Immunology Authors: Shahabi S, Mohammadzadeh Hajipirloo H, Keramati A, Hazrati Tappeh K, Bozorgomid A Tags: Iran J Allergy Asthma Immunol Source Type: research

Waning Immunity and Microbial Vaccines - Workshop of the National Institute of Allergy and Infectious Diseases.
Abstract Since the middle of the 20th century, vaccines have made a significant public health impact controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents with complex life cycles and antigenic variation remains a key challenge. Novel strategies to characterize the short and long-term immune responses to vaccines, and to induce immune responses that mimic natural infection have recently emerged. New technologies and ...
Source: Clinical and Vaccine Immunology - May 10, 2017 Category: Allergy & Immunology Authors: Gu XX, Plotkin SA, Edwards KM, Sette A, Mills KHG, Levy O, Sant AJ, Mo A, Alexander W, Lu KT, Taylor CE Tags: Clin Vaccine Immunol Source Type: research

Non-classical B Cell Memory of Allergic IgE Responses
Sean P. Saunders1, Erica G. M. Ma1,2, Carlos J. Aranda1 and Maria A. Curotto de Lafaille1,3* 1Division of Pulmonary, Critical Care and Sleep Medicine, Laboratory of Allergy and Inflammation, Department of Medicine, New York University, New York, NY, United States 2Sackler Institute of Graduate Biomedical Sciences, New York University, New York, NY, United States 3Department of Cell Biology, New York University School of Medicine, New York, NY, United States The long-term effectiveness of antibody responses relies on the development of humoral immune memory. Humoral immunity is maintained by long-lived plasma ce...
Source: Frontiers in Immunology - April 25, 2019 Category: Allergy & Immunology Source Type: research

Expanding Research Capacity in Sub-Saharan Africa Through Informatics, Bioinformatics, and Data Science Training Programs in Mali
Conclusion Bioinformatics and data science training programs in developing countries necessitate incremental and collaborative strategies for their feasible and sustainable development. The progress described here covered decades of collaborative efforts centered on training and research on computationally intensive topics. These efforts laid the groundwork and platforms conducive for hosting a bioinformatics and data science training program in Mali. Training programs are perhaps best facilitated through Africa’s university systems as they are perhaps best positioned to maintain core resources during lapses in sho...
Source: Frontiers in Genetics - April 11, 2019 Category: Genetics & Stem Cells Source Type: research

From “Serum Sickness” to “Xenosialitis”: Past, Present, and Future Significance of the Non-human Sialic Acid Neu5Gc
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human dis...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

NIH-funded study reveals why malaria vaccine only partially protected children, infants
(NIH/National Institute of Allergy and Infectious Diseases) Using new, highly sensitive genomic sequencing technology, an international team of researchers has found new biological evidence to help explain why the malaria vaccine candidate RTS,S/AS01 (called RTS,S) provided only moderate protection among vaccinated children during clinical testing. The researchers, funded in part by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, found that genetic variability in the surface protein targeted by the RTS,S vaccine likely played a significant role.
Source: EurekAlert! - Infectious and Emerging Diseases - October 22, 2015 Category: Infectious Diseases Source Type: news

Experimental malaria vaccine offers durable protection against many strains in NIH trial
(NIH/National Institute of Allergy and Infectious Diseases) An investigational malaria vaccine has protected a small number of healthy US adults from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy of Sciences (PNAS). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and co-conducted the Phase 1 clinical trial.
Source: EurekAlert! - Infectious and Emerging Diseases - February 21, 2017 Category: Infectious Diseases Source Type: news

NIH begins study of vaccine to protect against mosquito-borne diseases
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections. The study, conducted at the NIH Clinical Center in Bethesda, Maryland, will examine the vaccine's safety and ability to generate an immune response.
Source: EurekAlert! - Infectious and Emerging Diseases - February 21, 2017 Category: Infectious Diseases Source Type: news

A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis
Malaria is the single leading cause of mortality, especially among children in the developing world. Typhoid fever, caused by infection withSalmonella typhi, is known to be endemic with malaria and causes its own significant disease burden. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response againstSalmonella typhi...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Modified experimental vaccine protects monkeys from deadly malaria
(NIH/National Institute of Allergy and Infectious Diseases) Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, modified an experimental malaria vaccine and showed that it completely protected four of eight monkeys that received it against challenge with the virulent Plasmodium falciparum malaria parasite. In three of the remaining four monkeys, the vaccine delayed when parasites first appeared in the blood by more than 25 days.
Source: EurekAlert! - Infectious and Emerging Diseases - May 22, 2017 Category: Infectious Diseases Source Type: news

New malaria vaccine could save millions of lives
Conclusion This is a promising step in the long struggle by scientists to develop a safe and effective vaccine against P. falciparum malaria. However, this was a tiny, early stage study and more research is required to replicate the results and to look further at the potential effectiveness of different doses. It is not certain how long such a vaccine may offer protection for and also, whether it would protect against other strains than the one tested here.  Travellers to malarial areas are strongly advised to avoid mosquito bites by using insect repellent and mosquito nets, and by covering up at all times. Medication ma...
Source: NHS News Feed - August 9, 2013 Category: Consumer Health News Tags: Medication Medical practice Source Type: news

Nigeria: Nigerian Medical Experts Applaud Investigational Malaria Vaccine
[Vanguard]NIGERIAN medical professionals have applauded the early-stage clinical evaluation of an investigational malaria vaccine known as the PfSPZ Vaccine, conducted by researchers at the National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health.
Source: AllAfrica News: Malaria - August 13, 2013 Category: Infectious Diseases Source Type: news

NIAID meeting report: Improving malaria vaccine strategies through the application of immunological principles.
This report summarizes the discussion and major recommendations generated by the workshop participants regarding the application of recent advances in basic immunology and state-of-the-art immunological tools to improve progress and help address current challenges and knowledge gaps in malaria vaccine development. PMID: 24060568 [PubMed - as supplied by publisher]
Source: Vaccine - September 20, 2013 Category: Allergy & Immunology Authors: Mo AX, Augustine AD Tags: Vaccine Source Type: research

Malaria vaccines: past, present and future
The currently available malaria control tools have allowed malaria elimination in many regions but there remain many regions where malaria control has made little progress. A safe and protective malaria vaccine would be a huge asset for malaria control. Despite the many challenges, efforts continue to design and evaluate malaria vaccine candidates. These candidates target different stages in the life cycle of Plasmodia. The most advanced vaccine candidates target the pre-erythrocytic stages in the life cycle of the parasite and include RTS,S/AS01, which has progressed through clinical development to the stage that it may b...
Source: Archives of Disease in Childhood - November 12, 2013 Category: Pediatrics Authors: von Seidlein, L., Bejon, P. Tags: Immunology (including allergy), Drugs: infectious diseases, ADC Global child health, Travel medicine, Tropical medicine (infectious diseases), Vaccination / immunisation Source Type: research

Scientists identify potential vaccine candidate for pediatric malaria
(NIH/National Institute of Allergy and Infectious Diseases) Researchers have identified a substance, or antigen, that generates antibodies that can hinder the ability of malaria parasites to multiply, which may protect against severe malaria infection. The antigen, known as PfSEA-1, was associated with reduced parasite levels among children and adults in malaria-endemic areas.
Source: EurekAlert! - Infectious and Emerging Diseases - May 22, 2014 Category: Infectious Diseases Source Type: news